TrialDiabetes, obesity & metabolism2021

Effect of exenatide twice daily and dapagliflozin, alone and in combination, on markers of kidney function in obese patients with type 2 diabetes: A prespecified secondary analysis of a randomized controlled clinical trial.

Charlotte C van Ruiten et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.